Recombinant measles virus
OwnerMisako Yoneda, Chieko Kaiinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a recombinant measles virus useful as a live vaccine against COVID-19 and a vector used for production of the recombinant measles virus. That is, the present invention relates to a recombinant measles virus having a gene encoding a protein of the coronavirus SARS-COV-2 inserted between the N gene region and the P gene region in a measles virus genome; the recombinant measles virus in which the protein is a spike protein of SARS-COV-2 or a partial protein thereof; and a DNA in which a gene encoding a protein of SARS-COV-2 is inserted in a region ranging from the 1,686th base to the 1,694th base of a base sequence set forth in SEQ ID NO: 2.
Claims16
A recombinant measles virus, comprising:
- a gene encoding a protein of coronavirus SARS-COV-2 inserted between an N gene region and a P gene region in a measles virus genome.
An RNA consisting of a base sequence complementary to a base sequence set forth in SEQ ID NO:
- 3, or a DNA consisting of a base sequence set forth in SEQ ID NO:
- 3, or a plasmid vector comprising a DNA consisting of a base sequence set forth in SEQ ID NO:
- 1.
A DNA comprising:
- a gene encoding a protein of SARS-COV-2 inserted into:
- a region ranging from a 1,686th base to a 1,694th base in a base sequence set forth in SEQ ID NO:
- 2, or
- an Fse I recognition sequence located from a 1,686th base to a 1,694th base of a base sequence set forth in SEQ ID NO:
- 1.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.